SCF ENCYCLOPEDIA ENTRY

SECONDARY (DELAYED) POSTPARTUM HEMORRHAGE

SCF-RDOS Registry Code: SCF-RDOS-PPD-HM-002

Disease Type Classification: Hematologic and Obstetric Disorder → Delayed Postpartum Hemorrhagic Disease → Secondary Postpartum Hemorrhage Syndrome

Adaptive Module Activation:

• Universal Core Module
• Hematologic Disease Expansion
• Vascular Injury Expansion
• Endometrial Regeneration Expansion
• Obstetric Recovery Expansion
• Infectious Disease Expansion
• Coagulation System Expansion

1. SCOPE & POSITIONING

Etiology / Classification

Secondary Postpartum Hemorrhage (SPPH), also known as Delayed Postpartum Hemorrhage, is defined as excessive uterine bleeding occurring after the first 24 hours postpartum and up to 12 weeks following delivery.

Unlike Primary Postpartum Hemorrhage, which occurs immediately after childbirth, Secondary Postpartum Hemorrhage develops during the postpartum recovery period and is commonly associated with:

• Retained products of conception (RPOC)
• Subinvolution of the placental implantation site
• Endometritis
• Uterine infection
• Coagulation disorders
• Uterine vascular abnormalities
• Cesarean scar healing abnormalities

Within the SCF framework, Secondary Postpartum Hemorrhage is classified as:

A postpartum uterovascular recovery failure syndrome characterized by delayed hemostatic destabilization, defective endometrial regeneration, persistent placental-bed vascular activity, inflammatory disruption, or coagulation dysfunction resulting in recurrent maternal hemorrhage.

SCF Classification

SCF Disease Category: Delayed Hemostatic Recovery Failure Syndrome

SCF Functional Class:

Maternal Postpartum Uterovascular Remodeling Dysfunction Disorder

SCF Fault Tier Classification

Clinical Significance

Secondary Postpartum Hemorrhage is a major cause of postpartum hospital readmission and may result in severe maternal morbidity if unrecognized.

Potential complications include:

• Severe anemia
• Hemodynamic instability
• Recurrent hemorrhage
• Endometritis
• Sepsis
• Blood transfusion requirement
• Emergency surgical intervention
• Hysterectomy
• Maternal mortality (rare but documented)

SCF Domain Alignment

Primary Domains:

• Hematologic
• Obstetric
• Uterine
• Vascular

Secondary Domains:

• Infectious
• Endometrial
• Endocrine
• Immune

2. ETIOPATHOGENIC CORE

Primary Cause

Secondary Postpartum Hemorrhage develops through failure of complete postpartum uterine involution and restoration of normal placental-bed vascular integrity.

Major etiologic pathways include:

Pathway A — Retained Products of Conception

Persistent placental or fetal tissue maintains:

• Angiogenic activity
• Vascular perfusion
• Inflammatory signaling

Result:

• Continued uterine bleeding

Pathway B — Placental Site Subinvolution

Failure of physiologic regression of:

• Spiral arteries
• Placental bed vasculature

Result:

• Delayed vascular closure

Pathway C — Endometritis

Infection causes:

• Endometrial inflammation
• Tissue necrosis
• Vascular instability

Result:

• Hemorrhagic recurrence

Pathway D — Coagulation Dysfunction

Includes:

• Inherited bleeding disorders
• Acquired coagulopathies
• Delayed coagulation instability

Result:

• Failure of durable hemostasis

Pathway E — Uterine Vascular Lesions

Examples:

• Uterine artery pseudoaneurysm
• Arteriovenous malformation
• Cesarean scar vascular defects

Result:

• Sudden catastrophic bleeding

3. SCF FAULT ARCHITECTURE

4. PATHOGENESIS FLOW (SCF LOGIC)

Delivery

↓

Initial Hemostasis Achieved

↓

Postpartum Recovery Phase

↓

Incomplete Placental Bed Remodeling

and/or

Retained Tissue

and/or

Endometritis

and/or

Vascular Lesion

↓

Persistent Vascular Activity

↓

Endometrial Instability

↓

Delayed Vessel Reopening

↓

Secondary Uterine Bleeding

↓

Progressive Blood Loss

↓

Anemia

↓

Hemodynamic Instability

↓

Severe Maternal Morbidity

5. CLINICAL SPECTRUM

6. SCF TRINITY FRAMEWORK MAPPING

Trinity Axis I — Structural Integrity

Affected Systems:

• Endometrium
• Placental implantation site
• Uterine vasculature
• Myometrium

Primary Failure:

• Incomplete uterine structural recovery

Trinity Axis II — Energetic Integrity

Affected Systems:

• Tissue regeneration pathways
• Cellular repair systems
• Mitochondrial recovery networks

Primary Failure:

• Delayed regenerative recovery

Trinity Axis III — Informational Integrity

Affected Systems:

• Hemostatic signaling pathways
• Endometrial repair signaling
• Inflammatory regulation networks

Primary Failure:

• Uterine recovery desynchronization

7. HEMORRHAGE EXPANSION MODULE

Clinical Subtype Registry

Type A

Retained Products Hemorrhage

Characteristics:

• Most common cause
• Persistent placental tissue

Type B

Placental Site Subinvolution Syndrome

Characteristics:

• Failure of spiral artery involution
• Delayed vascular closure

Type C

Infectious Hemorrhage Syndrome

Characteristics:

• Endometritis-associated bleeding
• Fever and uterine tenderness

Type D

Coagulopathic Secondary Hemorrhage

Characteristics:

• Underlying bleeding disorder
• Persistent hemostatic instability

Type E

Vascular Lesion Hemorrhage

Characteristics:

• Uterine artery pseudoaneurysm
• Arteriovenous malformation
• High-risk catastrophic bleeding

8. MULTI-OMICS PATHOGENESIS MAP

9. SCF PCR THERAPEUTIC STRATEGY

PREVENTATIVE

Objectives

Prevent delayed postpartum hemorrhage.

Targets:

• Placental completeness
• Uterine involution
• Infection prevention
• Hemostatic optimization

CURATIVE

Objectives

Identify and eliminate the bleeding source.

Targets:

• Retained tissue
• Infection
• Vascular lesions
• Coagulopathy

Interventions:

• Uterotonic therapy
• Antibiotic therapy when indicated
• Surgical evacuation when required
• Hemostatic correction
• Interventional radiology procedures

RESTORATIVE

Objectives

Restore normal uterine architecture and vascular stability.

Targets:

• Endometrial regeneration
• Placental-bed remodeling
• Vascular healing
• Hematologic recovery

Potential strategies:

• Precision uterine regenerative platforms
• Endometrial recovery systems
• SCF-derived hemostatic stabilization therapeutics
• Vascular remodeling optimization approaches

10. CURRENT STANDARD OF CARE

Diagnostic Evaluation

Clinical Assessment

• Bleeding pattern assessment
• Hemodynamic evaluation
• Infection screening
• Obstetric history review

Laboratory Evaluation

• Complete blood count
• Coagulation profile
• Fibrinogen
• Inflammatory markers
• Blood typing and crossmatch

Imaging

Primary:

• Pelvic ultrasound

Advanced:

• Doppler ultrasonography
• CT angiography
• MRI when indicated

Treatment

Medical Management

• Uterotonic agents
• Antibiotics when infection is suspected
• Hemostatic support

Procedural Management

• Dilation and curettage
• Hysteroscopic tissue removal
• Balloon tamponade

Advanced Intervention

• Uterine artery embolization
• Surgical vessel ligation
• Hysterectomy in refractory cases

11. SCF THERAPEUTIC ENGINEERING OPPORTUNITIES

SCF Target Cluster A

Endometrial Regeneration Platform

Targets:

• Endometrial repair pathways
• Tissue regeneration signaling
• Uterine recovery networks

SCF Target Cluster B

Vascular Remodeling Platform

Targets:

• Spiral artery involution
• Placental-bed vascular closure
• Endothelial stabilization

SCF Target Cluster C

Precision Hemostasis Platform

Targets:

• Coagulation cascade optimization
• Platelet function enhancement
• Fibrin stabilization

SCF Target Cluster D

Anti-Inflammatory Recovery Platform

Targets:

• Endometritis-associated inflammation
• Cytokine dysregulation
• Tissue injury amplification pathways

12. TRANSLATIONAL BLUEPRINT

Diagnostic Biomarkers

Hematologic

• Hemoglobin
• Hematocrit
• Platelet count
• Fibrinogen

Endometrial Injury

• Regenerative biomarkers
• Angiogenic markers

Inflammatory

• CRP
• IL-6
• Procalcitonin (when infection suspected)

Vascular

• VEGF
• Endothelial injury markers

Clinical Endpoints

Primary:

• Complete hemorrhage resolution

Secondary:

• Restoration of uterine involution
• Correction of anemia
• Prevention of recurrence
• Preservation of fertility

FDA Translational Pathway

Preclinical

↓

IND

↓

Phase I Safety

↓

Phase II Proof-of-Concept

↓

Phase III Maternal Outcomes

↓

NDA/BLA Submission

13. SCF DBI INTERPRETATION

Decentralized Biological Intelligence Failure

Cellular Layer

Endometrial, endothelial, and hemostatic cells fail to coordinate complete postpartum recovery.

Tissue Layer

The placental implantation site remains biologically active beyond its intended lifespan.

Organ Layer

The uterus fails to complete normal involution and vascular remodeling.

System Layer

Hemostatic, regenerative, inflammatory, and vascular recovery systems become desynchronized.

Whole-Organism Layer

Maternal postpartum healing becomes destabilized by delayed hemorrhagic reactivation during the recovery phase.

14. SCF LAYMAN’S SUMMARY

Secondary (Delayed) Postpartum Hemorrhage is excessive bleeding that occurs after the first day following childbirth, sometimes appearing days or even weeks after delivery.

According to the SCF model, the condition develops when the uterus does not fully complete its healing process after birth. Retained placental tissue, infection, abnormal blood vessels, or incomplete closure of placental-bed arteries can cause bleeding to restart after an initially normal recovery.

Common symptoms include:

• Sudden heavy vaginal bleeding
• Passage of large blood clots
• Dizziness
• Fatigue
• Pelvic pain
• Fever (if infection is present)
• Signs of anemia

Prompt evaluation is important because delayed hemorrhage can rapidly become serious despite occurring well after delivery.

SCF-RDOS INDICATION SUMMARY